CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Phaxiam Therapeutics SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Phaxiam Therapeutics SA
60 avenue Rockefeller
Phone: +33 478744438p:+33 478744438 LYON, 69008  France Ticker: PHXMPHXM
Business Summary
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Jean-PaulKress 59 6/21/2019 6/21/2019
Chief Executive Officer, Director GilBeyen 61 6/21/2019 8/1/2012
Chief Financial Officer, Chief Operating Officer, Deputy General Manager EricSoyer 56 1/1/2019 9/1/2015
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Erytech Pharma SA 60 Avenue Rockefeller Lyon France
Pherecydes Pharma SA 22, Boulevard Benoni Goullin Nantes France
Pherecydes Pharma SA 22, boulevard Benoni Goullin NANTES France

Business Names
Business Name
0QSS
ERYP
ERYtech Pharma
4 additional Business Names available in full report.

General Information
Number of Employees: 51 (As of 12/31/2023)
Outstanding Shares: 6,074,855 (As of 12/31/2023)
Stock Exchange: EPA
Fax Number: +33 478755629


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024